BioCryst Pharmaceuticals(NASDAQ) BCRX

BioCryst makes easy-to-take pills for people with rare diseases. Their drugs stop painful and dangerous body swelling. They also make flu medicine for clinics.

What Is in the Medicine Cabinet?

• ORLADEYO: Once-daily oral capsule or pellet treatment for hereditary angioedema (HAE), a condition causing severe swelling.
• Navenibart: Injectable treatment for HAE designed to be given every three or six months; currently in Phase 3 clinical testing.
• RAPIVAB: Intravenous flu medicine used for adults and children as young as six months old.
• BCX17725: Investigational protein therapy for Netherton syndrome, a rare genetic disorder that damages the skin barrier.
• Avoralstat: Eye medicine in early testing to treat vision loss caused by fluid leaks in patients with diabetes.

Mergers and Global Partnerships

• Merged with Astria Therapeutics, Inc. on January 23, 2026, to acquire a potential best-in-class injectable treatment for HAE.
• Sold the European business for ORLADEYO to Neopharmed Gentili S.p.A. on October 1, 2025, for $250 million in cash.
• Formed a license agreement with Kaken Pharmaceutical Co., Ltd. in August 2025 to develop and sell navenibart in Japan.
• Collaborated with Pint Pharma GmbH to register and promote HAE treatments across the pan-Latin America region.
• Awarded a contract by the U.S. Department of Health and Human Services in 2024 for up to $69 million in flu medicine.

How BioCryst Stays Competitive

BioCryst uses structure-guided drug design to create small molecules that fit specific protein targets like a key in a lock. The company manages a worldwide supply network and partners with local experts to sell its rare disease treatments in dozens of countries.

Strong Recent Performance

• Revenue reached $406.6 million in Q4 2025, up 209.1% from $131.5 million in Q4 2024.
• Operating income hit $260.4 million in Q4 2025, up from a $4.5 million loss in the previous year.
• Net income rose to $245.8 million in Q4 2025, up 1,017.5% year-over-year.
• Free cash flow reached $275.2 million in Q4 2025, up from a loss of $5.9 million in Q4 2024.

Bottom Line

BioCryst has evolved from a research-focused firm into a profitable commercial enterprise with global operations. The company is now using its cash and recent merger to expand its reach in the rare disease market.